KR102520411B1 - 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르 - Google Patents

종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르 Download PDF

Info

Publication number
KR102520411B1
KR102520411B1 KR1020217002286A KR20217002286A KR102520411B1 KR 102520411 B1 KR102520411 B1 KR 102520411B1 KR 1020217002286 A KR1020217002286 A KR 1020217002286A KR 20217002286 A KR20217002286 A KR 20217002286A KR 102520411 B1 KR102520411 B1 KR 102520411B1
Authority
KR
South Korea
Prior art keywords
carcinoma
cortexolone
compound
treatment
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002286A
Other languages
English (en)
Korean (ko)
Other versions
KR20210012047A (ko
Inventor
마라 제르로니
Original Assignee
코스모 테크놀러지스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스모 테크놀러지스 리미티드 filed Critical 코스모 테크놀러지스 리미티드
Priority to KR1020237011743A priority Critical patent/KR102712584B1/ko
Publication of KR20210012047A publication Critical patent/KR20210012047A/ko
Application granted granted Critical
Publication of KR102520411B1 publication Critical patent/KR102520411B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020217002286A 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르 Active KR102520411B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237011743A KR102712584B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14188063.3A EP3006453A1 (en) 2014-10-08 2014-10-08 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP14188063.3 2014-10-08
KR1020177011114A KR102248983B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
PCT/EP2015/073172 WO2016055533A1 (en) 2014-10-08 2015-10-07 17a,21-diesters of cortexolone for use in the treatment of tumors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177011114A Division KR102248983B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011743A Division KR102712584B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Publications (2)

Publication Number Publication Date
KR20210012047A KR20210012047A (ko) 2021-02-02
KR102520411B1 true KR102520411B1 (ko) 2023-04-11

Family

ID=51687868

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020217002286A Active KR102520411B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR1020247032041A Pending KR20240149968A (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR1020177011239A Withdrawn KR20170063821A (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론 17α-벤조에이트
KR1020237011743A Active KR102712584B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR1020177011114A Active KR102248983B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020247032041A Pending KR20240149968A (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR1020177011239A Withdrawn KR20170063821A (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론 17α-벤조에이트
KR1020237011743A Active KR102712584B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR1020177011114A Active KR102248983B1 (ko) 2014-10-08 2015-10-07 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Country Status (23)

Country Link
US (8) US10183030B2 (https=)
EP (4) EP3006453A1 (https=)
JP (5) JP6503057B2 (https=)
KR (5) KR102520411B1 (https=)
CN (5) CN107074905B (https=)
AU (3) AU2015330003A1 (https=)
BR (2) BR112017007076B1 (https=)
CA (3) CA2962746A1 (https=)
DK (2) DK3456330T3 (https=)
ES (3) ES2713699T3 (https=)
HR (2) HRP20190194T1 (https=)
HU (2) HUE055143T2 (https=)
IL (3) IL272095B2 (https=)
LT (2) LT3204400T (https=)
MX (3) MX385557B (https=)
PL (2) PL3456330T3 (https=)
PT (2) PT3456330T (https=)
RS (2) RS58607B1 (https=)
RU (2) RU2712752C2 (https=)
SI (2) SI3456330T1 (https=)
TR (1) TR201901422T4 (https=)
WO (2) WO2016055537A1 (https=)
ZA (2) ZA201702209B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230052990A (ko) * 2014-10-08 2023-04-20 코스모 테크놀러지스 리미티드 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
MX2019011543A (es) 2017-03-31 2019-12-16 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11464764B2 (en) 2018-12-19 2022-10-11 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
CN110698527B (zh) * 2019-11-19 2022-08-26 湖南新合新生物医药有限公司 一种高纯度氢化可的松-17-戊酸酯的制备方法
WO2021242912A1 (en) 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
CN112028956A (zh) * 2020-09-10 2020-12-04 那路新 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用
CN116135871A (zh) * 2021-11-16 2023-05-19 石家庄迪斯凯威医药科技有限公司 一种具有抗耐药性的抗菌化合物
KR20250073629A (ko) 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE619180A (fr) * 1961-06-24 1962-12-20 Vismara Francesco Spa 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation
CH429716A (de) * 1961-06-24 1967-02-15 Vismara Francesco Spa Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden
NL6605514A (https=) 1966-04-25 1967-10-26
EP0001737B1 (de) * 1977-10-26 1981-01-07 Schering Aktiengesellschaft 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
DE2748442C3 (de) 1977-10-26 1981-08-27 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
DE3169460D1 (en) * 1980-12-23 1985-04-25 Schering Ag 6-alpha-methyl hydrocortisone derivatives, their preparation and their utilization
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4920216A (en) * 1987-05-28 1990-04-24 The Trustees Of Columbia In The City Of New York Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
DK0464153T3 (da) 1989-02-07 1995-04-24 Upjohn Co Dehalogenering af organiske forbindelser under anvendelse af tin eller bly
DE4121484A1 (de) 1991-06-26 1993-01-07 Schering Ag Verfahren zur herstellung von 6-methylensteroiden
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
AU1770901A (en) 2000-11-16 2002-05-27 Alcon Lab Inc Combination therapy for lowering and controlling intraocular pressure
ITMI20011762A1 (it) * 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
ITMI20051695A1 (it) * 2005-09-14 2007-03-15 Cosmo Spa Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
DE102006059063A1 (de) 2005-12-24 2007-06-28 Bayer Healthcare Ag Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
ITMI20071616A1 (it) * 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CN101397317A (zh) 2007-09-27 2009-04-01 天津药业研究院有限公司 一种新型硝酸酯类甾体化合物
CA2708149A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
JP2010515777A (ja) 2008-03-18 2010-05-13 シコール インコーポレイティド 空気感受性ステロイドの精製
EP3355057A3 (en) * 2010-06-01 2018-12-12 Metanomics Health GmbH Means and methods for diagnosing pancreatic cancer in a subject
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
RU2506974C1 (ru) 2012-11-06 2014-02-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения первично нерезектабельного рака легкого
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
EP3006453A1 (en) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Giuseppe Celasco 등, Arzneimittelforschung, 2005 Vol. 55, Iss. 10, pp. 581-587
Patrizia Ferraboschi 등, Tetrahedron Letters, 2008, Vol. 49, pp. 4610-4612

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230052990A (ko) * 2014-10-08 2023-04-20 코스모 테크놀러지스 리미티드 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
KR102712584B1 (ko) * 2014-10-08 2024-10-04 코스모 테크놀러지스 리미티드 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Also Published As

Publication number Publication date
RU2017115771A (ru) 2018-11-12
WO2016055533A1 (en) 2016-04-14
JP6735739B2 (ja) 2020-08-05
EP3006453A1 (en) 2016-04-13
CN107074905A (zh) 2017-08-18
HUE055143T2 (hu) 2021-11-29
CN111285913B (zh) 2023-01-10
CN115671114A (zh) 2023-02-03
KR20230052990A (ko) 2023-04-20
JP6503057B2 (ja) 2019-04-17
IL251028A0 (en) 2017-04-30
IL272095A (en) 2020-03-31
RU2712752C2 (ru) 2020-01-31
RU2017115773A3 (https=) 2019-03-15
US20190175618A1 (en) 2019-06-13
MX2017004660A (es) 2017-10-16
AU2015329999B2 (en) 2020-01-23
KR20240149968A (ko) 2024-10-15
US10231980B2 (en) 2019-03-19
US20170304318A1 (en) 2017-10-26
PT3204400T (pt) 2019-02-25
ES2713699T3 (es) 2019-05-23
CN107074905B (zh) 2019-08-09
RS58607B1 (sr) 2019-05-31
RU2020102939A (ru) 2020-05-20
PL3456330T3 (pl) 2021-11-15
RU2017115771A3 (https=) 2019-03-11
HRP20211177T1 (hr) 2021-10-29
KR20210012047A (ko) 2021-02-02
EP3456330A1 (en) 2019-03-20
AU2015329999A1 (en) 2017-04-06
KR20170063821A (ko) 2017-06-08
RU2017115773A (ru) 2018-11-15
CA3160391C (en) 2024-06-25
MX366294B (es) 2019-07-04
US11986484B2 (en) 2024-05-21
LT3204400T (lt) 2019-04-10
EP3204400A1 (en) 2017-08-16
ES2806094T3 (es) 2021-02-16
DK3204400T3 (en) 2019-03-04
CN116102604A (zh) 2023-05-12
ZA201902320B (en) 2022-11-30
PL3204400T3 (pl) 2019-05-31
SI3456330T1 (sl) 2021-09-30
US20230128438A1 (en) 2023-04-27
JP2017530184A (ja) 2017-10-12
US10646497B2 (en) 2020-05-12
MX2017004661A (es) 2017-10-16
IL272095B2 (en) 2023-04-01
IL272095B (en) 2022-12-01
JP2019070033A (ja) 2019-05-09
US20240277731A1 (en) 2024-08-22
KR20170063799A (ko) 2017-06-08
CA2960928A1 (en) 2016-04-14
WO2016055537A1 (en) 2016-04-14
CA2962746A1 (en) 2016-04-14
US20200215080A1 (en) 2020-07-09
MX385557B (es) 2025-03-18
CN111285913A (zh) 2020-06-16
US20210299145A1 (en) 2021-09-30
CN107001406B (zh) 2020-03-27
EP3456330B1 (en) 2021-05-19
CA3160391A1 (en) 2016-04-14
CN107001406A (zh) 2017-08-01
BR112017007076A2 (pt) 2017-12-26
CA2960928C (en) 2023-10-31
PT3456330T (pt) 2021-07-13
RU2712950C2 (ru) 2020-02-03
MX2019008063A (es) 2019-09-11
BR112017007076B1 (pt) 2023-12-19
DK3456330T3 (da) 2021-07-26
HUE041503T2 (hu) 2019-05-28
HRP20190194T1 (hr) 2019-04-19
JP7028809B2 (ja) 2022-03-02
ES2882223T3 (es) 2021-12-01
RS62147B1 (sr) 2021-08-31
EP3204012B1 (en) 2020-06-03
US10183030B2 (en) 2019-01-22
IL251028B (en) 2020-01-30
US11712443B2 (en) 2023-08-01
KR102712584B1 (ko) 2024-10-04
SI3204400T1 (sl) 2019-04-30
JP2017530171A (ja) 2017-10-12
EP3204400B1 (en) 2018-12-12
US10993949B2 (en) 2021-05-04
ZA201702209B (en) 2019-08-28
LT3456330T (lt) 2021-08-10
AU2020201446B2 (en) 2021-03-18
IL251371A0 (en) 2017-05-29
JP2020143140A (ja) 2020-09-10
TR201901422T4 (tr) 2019-02-21
BR112017007078A2 (pt) 2017-12-26
US20170360806A1 (en) 2017-12-21
AU2020201446A1 (en) 2020-05-14
KR102248983B1 (ko) 2021-05-10
AU2015330003A1 (en) 2017-04-13
US20190091240A1 (en) 2019-03-28
JP2021046418A (ja) 2021-03-25
EP3204012A1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
KR102520411B1 (ko) 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4